Daiichi Sankyo secures EMA validation for two cholesterol therapies
Daiichi Sankyo said the European Medicines Agency validated two of its triple-combination cholesterol therapies.
Related stories
InvestSMART Group Reports Quarterly Operating Loss of A$167,477
M impact | EQUITY | Oct 29, 2026, 10:45 PM UTC
STAKK Reports Q1 FY2027 Pro Forma Revenue of A$16.1 Million
STAKK reported unaudited pro forma group revenue of A$16.1 million for Q1 FY2027.
M impact | EQUITY | Oct 29, 2026, 10:45 PM UTC
Merit Medical Systems Reports Quarterly Results
Merit Medical Systems reported results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 10:44 PM UTC
Livium Reports Q1 FY27 Revenue of A$1.84 Million
Livium reported gross profit of A$0.95 million for Q1 FY27.
M impact | EQUITY | Oct 29, 2026, 10:44 PM UTC
Black Diamond Q3 Revenue Rises 52% on Resource and Infrastructure Demand
Black Diamond reported Q3 revenue up 52%, citing resource development and infrastructure demand.
M impact | EQUITY | Oct 29, 2026, 10:43 PM UTC
NVIDIA in Talks to Guarantee Billions in Debt for Nscale Data Center
NVIDIA is in talks to provide Nscale with billions in credit guarantees for debt to develop a 460-megawatt data center, The Information reports.
M impact | EQUITY | Oct 29, 2026, 10:43 PM UTC